These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 16632350)

  • 1. Development of N-2,4-pyrimidine-N-phenyl-N'-alkyl ureas as orally active inhibitors of tumor necrosis factor alpha (TNF-alpha) synthesis. Part 2.
    Maier JA; Brugel TA; Clark MP; Sabat M; Golebiowski A; Bookland RG; Laufersweiler MJ; Laughlin SK; Vanrens JC; De B; Hsieh LC; Brown KK; Juergens K; Walter RL; Janusz MJ
    Bioorg Med Chem Lett; 2006 Jul; 16(13):3514-8. PubMed ID: 16632350
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of N-2,4-pyrimidine-N-phenyl-N'-phenyl ureas as inhibitors of tumor necrosis factor alpha (TNF-alpha) synthesis. Part 1.
    Brugel TA; Maier JA; Clark MP; Sabat M; Golebiowski A; Bookland RG; Laufersweiler MJ; Laughlin SK; Vanrens JC; De B; Hsieh LC; Mekel MJ; Janusz MJ
    Bioorg Med Chem Lett; 2006 Jul; 16(13):3510-3. PubMed ID: 16632356
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of N-4,6-pyrimidine-N-alkyl-N'-phenyl ureas as orally active inhibitors of lymphocyte specific tyrosine kinase.
    Maier JA; Brugel TA; Sabat M; Golebiowski A; Laufersweiler MJ; VanRens JC; Hopkins CR; De B; Hsieh LC; Brown KK; Easwaran V; Janusz MJ
    Bioorg Med Chem Lett; 2006 Jul; 16(14):3646-50. PubMed ID: 16682201
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The development of novel inhibitors of tumor necrosis factor-alpha (TNF-alpha) production based on substituted [5,5]-bicyclic pyrazolones.
    Laufersweiler MJ; Brugel TA; Clark MP; Golebiowski A; Bookland RG; Laughlin SK; Sabat MP; Townes JA; VanRens JC; De B; Hsieh LC; Heitmeyer SA; Juergens K; Brown KK; Mekel MJ; Walter RL; Janusz MJ
    Bioorg Med Chem Lett; 2004 Aug; 14(16):4267-72. PubMed ID: 15261284
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of orally bioavailable bicyclic pyrazolones as inhibitors of tumor necrosis factor-alpha production.
    Clark MP; Laughlin SK; Laufersweiler MJ; Bookland RG; Brugel TA; Golebiowski A; Sabat MP; Townes JA; VanRens JC; Djung JF; Natchus MG; De B; Hsieh LC; Xu SC; Walter RL; Mekel MJ; Heitmeyer SA; Brown KK; Juergens K; Taiwo YO; Janusz MJ
    J Med Chem; 2004 May; 47(11):2724-7. PubMed ID: 15139749
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The development of monocyclic pyrazolone based cytokine synthesis inhibitors.
    Golebiowski A; Townes JA; Laufersweiler MJ; Brugel TA; Clark MP; Clark CM; Djung JF; Laughlin SK; Sabat MP; Bookland RG; VanRens JC; De B; Hsieh LC; Janusz MJ; Walter RL; Webster ME; Mekel MJ
    Bioorg Med Chem Lett; 2005 May; 15(9):2285-9. PubMed ID: 15837310
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 5-Cyanopyrimidine derivatives as a novel class of potent, selective, and orally active inhibitors of p38alpha MAP kinase.
    Liu C; Wrobleski ST; Lin J; Ahmed G; Metzger A; Wityak J; Gillooly KM; Shuster DJ; McIntyre KW; Pitt S; Shen DR; Zhang RF; Zhang H; Doweyko AM; Diller D; Henderson I; Barrish JC; Dodd JH; Schieven GL; Leftheris K
    J Med Chem; 2005 Oct; 48(20):6261-70. PubMed ID: 16190753
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of S-[5-amino-1-(4-fluorophenyl)-1H-pyrazol-4-yl]-[3-(2,3-dihydroxypropoxy)phenyl]methanone (RO3201195), an orally bioavailable and highly selective inhibitor of p38 MAP kinase.
    Goldstein DM; Alfredson T; Bertrand J; Browner MF; Clifford K; Dalrymple SA; Dunn J; Freire-Moar J; Harris S; Labadie SS; La Fargue J; Lapierre JM; Larrabee S; Li F; Papp E; McWeeney D; Ramesha C; Roberts R; Rotstein D; San Pablo B; Sjogren EB; So OY; Talamas FX; Tao W; Trejo A; Villasenor A; Welch M; Welch T; Weller P; Whiteley PE; Young K; Zipfel S
    J Med Chem; 2006 Mar; 49(5):1562-75. PubMed ID: 16509574
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The development of new isoxazolone based inhibitors of tumor necrosis factor-alpha (TNF-alpha) production.
    Laughlin SK; Clark MP; Djung JF; Golebiowski A; Brugel TA; Sabat M; Bookland RG; Laufersweiler MJ; VanRens JC; Townes JA; De B; Hsieh LC; Xu SC; Walter RL; Mekel MJ; Janusz MJ
    Bioorg Med Chem Lett; 2005 May; 15(9):2399-403. PubMed ID: 15837333
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of 4-(5-(cyclopropylcarbamoyl)-2-methylphenylamino)-5-methyl-N-propylpyrrolo[1,2-f][1,2,4]triazine-6-carboxamide (BMS-582949), a clinical p38α MAP kinase inhibitor for the treatment of inflammatory diseases.
    Liu C; Lin J; Wrobleski ST; Lin S; Hynes J; Wu H; Dyckman AJ; Li T; Wityak J; Gillooly KM; Pitt S; Shen DR; Zhang RF; McIntyre KW; Salter-Cid L; Shuster DJ; Zhang H; Marathe PH; Doweyko AM; Sack JS; Kiefer SE; Kish KF; Newitt JA; McKinnon M; Dodd JH; Barrish JC; Schieven GL; Leftheris K
    J Med Chem; 2010 Sep; 53(18):6629-39. PubMed ID: 20804198
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design, synthesis, and anti-inflammatory properties of orally active 4-(phenylamino)-pyrrolo[2,1-f][1,2,4]triazine p38alpha mitogen-activated protein kinase inhibitors.
    Hynes J; Dyckman AJ; Lin S; Wrobleski ST; Wu H; Gillooly KM; Kanner SB; Lonial H; Loo D; McIntyre KW; Pitt S; Shen DR; Shuster DJ; Yang X; Zhang R; Behnia K; Zhang H; Marathe PH; Doweyko AM; Tokarski JS; Sack JS; Pokross M; Kiefer SE; Newitt JA; Barrish JC; Dodd J; Schieven GL; Leftheris K
    J Med Chem; 2008 Jan; 51(1):4-16. PubMed ID: 18072718
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pyrazoloheteroaryls: novel p38alpha MAP kinase inhibiting scaffolds with oral activity.
    Revesz L; Blum E; Di Padova FE; Buhl T; Feifel R; Gram H; Hiestand P; Manning U; Neumann U; Rucklin G
    Bioorg Med Chem Lett; 2006 Jan; 16(2):262-6. PubMed ID: 16249085
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The discovery of orally active triaminotriazine aniline amides as inhibitors of p38 MAP kinase.
    Leftheris K; Ahmed G; Chan R; Dyckman AJ; Hussain Z; Ho K; Hynes J; Letourneau J; Li W; Lin S; Metzger A; Moriarty KJ; Riviello C; Shimshock Y; Wen J; Wityak J; Wrobleski ST; Wu H; Wu J; Desai M; Gillooly KM; Lin TH; Loo D; McIntyre KW; Pitt S; Shen DR; Shuster DJ; Zhang R; Diller D; Doweyko A; Sack J; Baldwin J; Barrish J; Dodd J; Henderson I; Kanner S; Schieven GL; Webb M
    J Med Chem; 2004 Dec; 47(25):6283-91. PubMed ID: 15566298
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis, evaluation and docking of novel pyrazolo pyrimidines as potent p38α MAP kinase inhibitors with improved anti-inflammatory, ulcerogenic and TNF-α inhibitory properties.
    Somakala K; Tariq S; Amir M
    Bioorg Chem; 2019 Jun; 87():550-559. PubMed ID: 30928877
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The development of new bicyclic pyrazole-based cytokine synthesis inhibitors.
    Townes JA; Golebiowski A; Clark MP; Laufersweiler MJ; Brugel TA; Sabat M; Bookland RG; Laughlin SK; VanRens JC; De B; Hsieh LC; Xu SC; Janusz MJ; Walter RL
    Bioorg Med Chem Lett; 2004 Oct; 14(19):4945-8. PubMed ID: 15341957
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design of potent and selective 2-aminobenzimidazole-based p38alpha MAP kinase inhibitors with excellent in vivo efficacy.
    de Dios A; Shih C; López de Uralde B; Sánchez C; del Prado M; Martín Cabrejas LM; Pleite S; Blanco-Urgoiti J; Lorite MJ; Nevill CR; Bonjouklian R; York J; Vieth M; Wang Y; Magnus N; Campbell RM; Anderson BD; McCann DJ; Giera DD; Lee PA; Schultz RM; Li LC; Johnson LM; Wolos JA
    J Med Chem; 2005 Apr; 48(7):2270-3. PubMed ID: 15801819
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The development of novel C-2, C-8, and N-9 trisubstituted purines as inhibitors of TNF-alpha production.
    Sabat M; Vanrens JC; Clark MP; Brugel TA; Maier J; Bookland RG; Laufersweiler MJ; Laughlin SK; Golebiowski A; De B; Hsieh LC; Walter RL; Mekel MJ; Janusz MJ
    Bioorg Med Chem Lett; 2006 Aug; 16(16):4360-5. PubMed ID: 16750367
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structure-based design of novel 2-amino-6-phenyl-pyrimido[5',4':5,6]pyrimido[1,2-a]benzimidazol-5(6H)-ones as potent and orally active inhibitors of lymphocyte specific kinase (Lck): synthesis, SAR, and in vivo anti-inflammatory activity.
    Martin MW; Newcomb J; Nunes JJ; Boucher C; Chai L; Epstein LF; Faust T; Flores S; Gallant P; Gore A; Gu Y; Hsieh F; Huang X; Kim JL; Middleton S; Morgenstern K; Oliveira-dos-Santos A; Patel VF; Powers D; Rose P; Tudor Y; Turci SM; Welcher AA; Zack D; Zhao H; Zhu L; Zhu X; Ghiron C; Ermann M; Johnston D; Saluste CG
    J Med Chem; 2008 Mar; 51(6):1637-48. PubMed ID: 18278858
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 2-(2-Furanyl)-7-phenyl[1,2,4]triazolo[1,5-c]pyrimidin-5-amine analogs: highly potent, orally active, adenosine A2A antagonists. Part 1.
    Matasi JJ; Caldwell JP; Zhang H; Fawzi A; Cohen-Williams ME; Varty GB; Tulshian DB
    Bioorg Med Chem Lett; 2005 Aug; 15(16):3670-4. PubMed ID: 15978806
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The design and synthesis of novel alpha-ketoamide-based p38 MAP kinase inhibitors.
    Montalban AG; Boman E; Chang CD; Ceide SC; Dahl R; Dalesandro D; Delaet NG; Erb E; Ernst JT; Gibbs A; Kahl J; Kessler L; Lundström J; Miller S; Nakanishi H; Roberts E; Saiah E; Sullivan R; Wang Z; Larson CJ
    Bioorg Med Chem Lett; 2008 Mar; 18(6):1772-7. PubMed ID: 18325768
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.